Zevra Ties NPC Testing Push To Valuation Gap And New CFO [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
Zevra Therapeutics (NasdaqGS:ZVRA) has partnered with GeneDx on a sponsored genetic testing program for Niemann Pick disease type C in the U.S. The program is designed to widen access to genomic testing and support earlier, more accurate NPC diagnosis. Zevra has also appointed Justin Renz as Chief Financial Officer and granted him an equity inducement award aligned with company and stakeholder interests. Zevra Therapeutics focuses on rare diseases, a segment where diagnosis can be slow and treatment options limited. By backing broader genetic testing for Niemann Pick disease type C, the company is tying its rare disease focus to real world diagnostic access. For readers tracking rare disease drug developers, this move connects scientific work with practical patient identification. The CFO appointment and equity inducement award point to an effort to deepen financial leadership while keeping incentives tied to long term company performance. For investors watching NasdaqGS:ZVRA
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics (ZVRA) is now covered by BTIG Research. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 3/9/26 - Beat
ZVRA
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 3
- 3/16/26 - Form 144
- ZVRA's page on the SEC website